New 'Off-the-Shelf' cancer therapy enters human testing for multiple advanced cancers
NCT ID NCT07216105
Summary
This early-stage study is testing FT836, a new type of 'off-the-shelf' CAR T-cell therapy, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how well the body tolerates FT836, which is given alone or combined with common chemotherapy drugs. Researchers will enroll about 113 adults with cancers like non-small cell lung, colorectal, breast, ovarian, and others to determine if this approach is safe enough for larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
-
University of Minnesota Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact
Conditions
Explore the condition pages connected to this study.